摘要
OBJECTIVE:To observe whether Jiedu granule(解毒颗粒,JDG)modulates the composition of the gut microbiota during advanced hepatocellular carcinoma(HCC).METHODS:A randomized controlled trial was conducted.Sixty-two advanced HCC participants were randomly allocated to receive JDG or placebo.The median overall survival(OS)times of patients and the variation of relative abundance of bacteria over time were used as main outcome measures.RESULTS:Patients who received JDG demonstrated significantly longer median OS times compared with the placebo group.Pyrosequencing of the V3 regions of 16S r RNA genes revealed a dose dependent deviation of gut microbiota in response to JDG treatment.Redundancy analysis identified Clostridium XI and Peptostreptococcaceae which related to the onset of liver cancer disappeared after 1-month and 2-month JDG treatment,while in control group,no significant changes of these two bacteria were found.The variation tendency of relative abundance of Bacteroides(essential in immunoblocking therapy of tumor)in JDG group was not obvious while in control group,it was decreased significantly with time.The relative abundance of Roseburia(correlated with the occurrence of liver cancer)was increased in JDG group and was decreased in control group over time.CONCLUSION:Changes in the gut microbiota may be associated with the efficiency of JDG on survival period of advanced HCC patients.Trial registration:Chinese Clinical TRIAL Registry Chi CTR-OOC-16008002.
基金
Supported by National Natural Science Foundation of China:the Value of Heat Clearing and Detoxification in the Treatment of Primary Liver Cancer from the Perspective of Tumor Inflammatory Microenvironment(No.81430101)
National Natural Science Foundation of China:to Explore the Mechanism of Sanshimao Granule on Anti-recurrence and Metastasis of Liver Cancer from the Perspective of Sec62 Regulating ER Stress(No.81473487)
National Natural Science Foundation of China:the Molecular Mechanism of Aconitum Decoction in Interfering with Immune Escape of Hepatocellular Carcinoma via Regulating the Spectrum Shift of NK Cell Receptor/Ligand(No.81774244)。
